HROW — Harrow Health, Inc. stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA

Latest market price

39.90

-0.54-1.34%

Overview Short InterestFilings

HROWQT52Harrow Health, Inc.·NASDAQ

Overview Short InterestFilings

39.90-1.34%

Earnings

Down 1.3% — Reported earnings — EPS missed by 86%, revenue missed by 16%.

High confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PAHC+0.99%$34.63 ALVO-0.13%$3.81 PRGO-2.18%$12.56 ANIP-2.04%$76.65 ETON-1.96%$43.73 CRON-2.87%$3.01 HCM+0.72%$12.60 PCRX-1.76%$24.58

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.40	Insider Own	-	Shs Outstand	37.28M	Perf Week	4.31%

Market Cap	1.51B	Forward P/E	17.32	EPS next Y	2.34	Insider Trans	-0.32%	Shs Float	28.72M	Perf Month	-5.80%

Enterprise Value	1.71B	PEG	0.45	EPS next Q	-	Inst Own	-	Short Float	23.83%	Perf Quarter	3.56%

Income	-14.92M	P/S	5.61	EPS this Y	158.13%	Inst Trans	-	Short Ratio	8.46	Perf Half Y	-12.20%

Sales	268.68M	P/B	52.45	EPS next Y	904.30%	ROA	-3.57%	Short Interest	6.84M	Perf YTD	-17.47%

Book/sh	-	P/C	99.03	EPS next 5Y	144.07%	ROE	-33.65%	52W High	54.12 -26.27%	Perf Year	22.47%

Cash/sh	-	P/FCF	105.58	EPS past 3/5Y	-	ROIC	8.55%	52W Low	28.16 41.70%	Perf 3Y	91.48%

Dividend Est.	-	EV/EBITDA	54.45	Sales past 3/5Y	45.12% 40.89%	Gross Margin	74.11%	Volatility	3.07% 4.72%	Perf 5Y	353.36%

Dividend TTM	-	EV/Sales	6.38	EPS Y/Y TTM	18.37%	Oper. Margin	10.47%	ATR (14)	1.90	Perf 10Y	936.92%

Dividend Ex-Date	-	Quick Ratio	2.30	Sales Y/Y TTM	34.50%	Profit Margin	-5.57%	RSI (14)	49.68	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	2.48	EPS Q/Q	-94.74%	SMA20	-1.46%	Beta	0.23	Target Price	73.67

Payout	0.00%	Debt/Eq	10.47	Sales Q/Q	-8.33%	SMA50	1.01%	Rel Volume	0.40	Prev Close	40.44

Employees	373	LT Debt/Eq	4.83	Earnings	Aug 10	SMA200	-1.62%	Avg Volume	804.12K	Price	39.90

IPO Date	Sep 28, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-85.66% -15.69%	Net Debt/EBITDA	6.55	Volume	322,836	Change	-1.34%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-13-26	Reiterated	Cantor Fitzgerald	Overweight	$94 → $88
Mar-18-26	Reiterated	BTIG	Buy	$63
Mar-04-26	Reiterated	HC Wainwright & Co.	Buy	$64 → $70
Nov-11-25	Reiterated	Cantor Fitzgerald		$76 → $94
Sep-29-25	Reiterated	Lake Street	Buy	$55 → $70
Sep-23-25	Reiterated	Craig-Hallum	Buy	$45 → $64
Aug-13-25	Reiterated	HC Wainwright & Co.	Buy	$64
Jul-11-25	Initiated	Cantor Fitzgerald amid path to growth	Overweight	$76
Oct-18-24	Reiterated	B.Riley Financial	Buy	$73
Oct-04-24	Reiterated	Lake Street	Buy	$25 → $55

Latest News

Aug-06-26

Aug-06-2601:56PM

Viatris Sharpens Focus with Divestiture, Hikes 2026 OutlookBenzinga

07:00AM

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Diseaseglobenewswire.com

Jul-27-26

Jul-27-2607:00AM

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026globenewswire.com

Jul-21-26

Jul-21-2605:51AM

BTIG Reiterates Buy on Harrow, Maintains $63 Price TargetBenzinga

Jul-20-26

Jul-20-2608:00AM

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026globenewswire.com

07:00AM

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meetingglobenewswire.com

Jul-15-26

Jul-15-2601:58PM

Harrow: Debt-Fueled Liquidity Masks An Operating Cash ProblemSeekingAlpha

Jul-06-26

Jul-06-2601:35PM

8 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga

Jul-01-26

Jul-01-2607:00AM

Harrow Announces Commercial Launch of BYOOVIZ® in the United Statesglobenewswire.com

07:00AM

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrowbusinesswire.com

Jun-13-26

Jun-13-2608:55PM

Is Harrow, Inc. (HROW) A Good Stock To Buy Now?Yahoo

Jun-12-26

Jun-12-2607:12AM

Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?Yahoo

Company

Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	269	272	200	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	69	68	49	—	—	—	—	—	—
Gross Profit	200	204	150	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	86	153	0	—	—	—	—	—	—
Research and Development	15	13	12	—	—	—	—	—	—
Other Operating Expense	70	0	130	—	—	—	—	—	—
Operating Income	28	39	9	—	—	—	—	—	—
Interest Expense	22	24	23	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-16	-16	-3	—	—	—	—	—	—
Net Income Before Taxes	-12	-2	-17	—	—	—	—	—	—
Income Taxes	4	3	0	—	—	—	—	—	—
Consolidated Net Income	-15	-5	-17	—	—	—	—	—	—
Net Income From Continuing Operations	-15	-5	-17	—	—	—	—	—	—
Net Income	-15	-5	-17	—	—	—	—	—	—
EPS (Recurring)	-0.39	-0.14	-0.49	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.39	-0.14	-0.49	—	—	—	—	—	—
EPS (Diluted)	-0.40	-0.14	-0.49	—	—	—	—	—	—
EBITDA	32	41	22	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	5.49	6.67	6.04	—	—	—	—	—	—
Gross Margin	74.35	75.00	75.00	—	—	—	—	—	—
Operating Margin	10.41	14.34	4.50	—	—	—	—	—	—
Net Margin	-5.58	-1.84	-8.50	—	—	—	—	—	—
Shares Outstanding	37	37	36	—	—	—	—	—	—
Market Capitalization	1,476	1,813	1,208	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Graves Adrienne L	Director	May 18 '26	Buy	31.07	1,000	31,070	1,000	May 19
SILVERNAIL LAUREN P	Director	May 18 '26	Buy	31.00	1,000	31,000	1,000	May 19
BAUM MARK L	CHIEF EXECUTIVE OFFICER	May 14 '26	Buy	30.20	10,000	302,000	2,996,130	May 15
BOLL ANDREW R.	PRESIDENT AND CFO	May 14 '26	Buy	29.90	3,500	104,650	814,679	May 15
Opaleye Management Inc.	10% Owner	Mar 04 '26	Sale	39.67	138,263	5,485,183	59,428	Mar 05
Opaleye Management Inc.	10% Owner	Mar 03 '26	Sale	39.15	60,309	2,361,242	63,691	Mar 05
Opaleye Management Inc.	10% Owner	Feb 27 '26	Sale	54.18	5,000	270,900	65,000	Mar 03
Opaleye Management Inc.	10% Owner	Jan 06 '26	Sale	53.35	20,000	1,066,914	70,000	Jan 08
BOLL ANDREW R.	PRESIDENT AND CFO	Dec 12 '25	Option Exercise	3.95	60,000	237,000	837,844	Dec 16
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Dec 12 '25	Option Exercise	3.95	180,000	711,000	3,066,124	Dec 16
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Jul 21 '25	Option Exercise	7.87	600,000	4,722,000	3,199,462	Jul 23
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Jul 31 '15	Option Exercise	7.87	600,000	4,722,000	0	Jul 23
Opaleye Management Inc.	10% Owner	Jun 10 '25	Sale	30.80	15,000	462,033	90,000	Jun 11
Opaleye Management Inc.	10% Owner	Jun 09 '25	Sale	30.37	15,204	461,794	105,000	Jun 11
Opaleye Management Inc.	10% Owner	Jun 04 '25	Sale	30.02	1,796	53,907	120,204	Jun 05

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.